Immediate Evolocumab After Heart Attack Improves LDL-Cholesterol Goals But Not Early Cardiovascular Outcomes

Results from the AMUNDSEN trial, presented at the ESC Congress 2026, show that immediate administration of evolocumab after a heart attack effectively improves LDL-cholesterol goals. However, the study did not demonstrate an improvement in early cardiovascular outcomes. These findings contribute to the ongoing understanding of optimal post-myocardial infarction treatment strategies.